Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
Emotional Effects of Methylphenidate and MDMA in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT01465685
- Locations
- π¨π
University Hospital Basel, Basel, Basel-Stadt, Switzerland
Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Lykos Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT01458327
- Locations
- πΊπΈ
Offices of Michael Mithoefer, Mount Pleasant, South Carolina, United States
-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2011-10-06
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 27
- Registration Number
- NCT01447472
- Locations
- πͺπΈ
IMIM-Hospital del Mar (Institut de Recerca Hospital del Mar), Barcelona, Spain
Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
- Conditions
- Interventions
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT01386177
- Locations
- π¨π
University Hospital Basel, Basel, Switzerland
Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)
- Conditions
- Interventions
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT01270672
- Locations
- π¨π
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland
Neurobiology and Pharmacokinets of Acute MDMA Administration
- Conditions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 187
- Registration Number
- NCT01148342
- Locations
- πΊπΈ
National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States
Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)
- Conditions
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT01136278
- Locations
- π¨π
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)
- Conditions
- Interventions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT00990067
- Locations
- π¨π
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland
Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)
- Conditions
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2009-06-15
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT00895804
- Locations
- π¨π
Heffter Research Center, University Hospital of Psychiatry, Zurich, Switzerland
Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)
- Conditions
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT00886886
- Locations
- π¨π
University Hospital, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.